Use of an Ang-(1-7) Receptor Agonist in Acute Lung Injury

With age-adjusted incidences of 86 per 100.000 person-years and overall mortality rates of about 43%, acute lung injury (ALI) and its most severe form, the acute respiratory distress syndrome (ARDS), remains a major cause of death in intensive care. So far, the only evident improvement for the survival of ARDS patients has been achieved by the implementation of minimal invasive ventilation strategies with low tidal volumes as compared to the previously used high tidal volumes. Ang-(1-7) or related agonists may represent a new and promising strategy for the treatment of ALI/ARDS. The present invention provides means and methods for a pharmacological intervention in the patho-physiologic events underlying ALI/ARDS.

Further Information: PDF

ipal GmbH
Phone: +49 (0)30/2125-4820

Contact
Ursula Haufe

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

Lighting up the future

New multidisciplinary research from the University of St Andrews could lead to more efficient televisions, computer screens and lighting. Researchers at the Organic Semiconductor Centre in the School of Physics and…

Researchers crack sugarcane’s complex genetic code

Sweet success: Scientists created a highly accurate reference genome for one of the most important modern crops and found a rare example of how genes confer disease resistance in plants….

Evolution of the most powerful ocean current on Earth

The Antarctic Circumpolar Current plays an important part in global overturning circulation, the exchange of heat and CO2 between the ocean and atmosphere, and the stability of Antarctica’s ice sheets….

Partners & Sponsors